Coeptis Therapeutics (COEP) Competitors $10.00 +0.73 (+7.87%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$9.83 -0.17 (-1.70%) As of 04/17/2025 05:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock COEP vs. PRQR, FDMT, NMRA, LRMR, NGNE, SCPH, OGI, ADCT, KOD, and TNXPShould you be buying Coeptis Therapeutics stock or one of its competitors? The main competitors of Coeptis Therapeutics include ProQR Therapeutics (PRQR), 4D Molecular Therapeutics (FDMT), Neumora Therapeutics (NMRA), Larimar Therapeutics (LRMR), Neurogene (NGNE), scPharmaceuticals (SCPH), Organigram (OGI), ADC Therapeutics (ADCT), Kodiak Sciences (KOD), and Tonix Pharmaceuticals (TNXP). These companies are all part of the "pharmaceutical products" industry. Coeptis Therapeutics vs. ProQR Therapeutics 4D Molecular Therapeutics Neumora Therapeutics Larimar Therapeutics Neurogene scPharmaceuticals Organigram ADC Therapeutics Kodiak Sciences Tonix Pharmaceuticals Coeptis Therapeutics (NASDAQ:COEP) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, community ranking, earnings, media sentiment, dividends, risk and analyst recommendations. Do institutionals & insiders hold more shares of COEP or PRQR? 13.9% of Coeptis Therapeutics shares are owned by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are owned by institutional investors. 24.3% of Coeptis Therapeutics shares are owned by company insiders. Comparatively, 8.4% of ProQR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has better valuation & earnings, COEP or PRQR? Coeptis Therapeutics has higher earnings, but lower revenue than ProQR Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Coeptis Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCoeptis TherapeuticsN/AN/A-$21.27M-$5.80-1.72ProQR Therapeutics$18.91M6.34-$30.43M-$0.34-3.35 Does the media prefer COEP or PRQR? In the previous week, ProQR Therapeutics had 6 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 9 mentions for ProQR Therapeutics and 3 mentions for Coeptis Therapeutics. ProQR Therapeutics' average media sentiment score of 0.82 beat Coeptis Therapeutics' score of -0.33 indicating that ProQR Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coeptis Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ProQR Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer COEP or PRQR? ProQR Therapeutics received 331 more outperform votes than Coeptis Therapeutics when rated by MarketBeat users. However, 83.33% of users gave Coeptis Therapeutics an outperform vote while only 61.99% of users gave ProQR Therapeutics an outperform vote. CompanyUnderperformOutperformCoeptis TherapeuticsOutperform Votes583.33% Underperform Votes116.67%ProQR TherapeuticsOutperform Votes33661.99% Underperform Votes20638.01% Is COEP or PRQR more profitable? Coeptis Therapeutics has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -134.31%. ProQR Therapeutics' return on equity of -71.58% beat Coeptis Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Coeptis TherapeuticsN/A -1,094.50% -219.97% ProQR Therapeutics -134.31%-71.58%-19.70% Do analysts rate COEP or PRQR? ProQR Therapeutics has a consensus target price of $9.50, indicating a potential upside of 733.33%. Given ProQR Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe ProQR Therapeutics is more favorable than Coeptis Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coeptis Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00ProQR Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Which has more volatility & risk, COEP or PRQR? Coeptis Therapeutics has a beta of -0.68, meaning that its share price is 168% less volatile than the S&P 500. Comparatively, ProQR Therapeutics has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500. SummaryProQR Therapeutics beats Coeptis Therapeutics on 13 of the 18 factors compared between the two stocks. Get Coeptis Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for COEP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COEP vs. The Competition Export to ExcelMetricCoeptis TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$33.65M$2.84B$5.31B$7.35BDividend YieldN/A1.86%5.45%4.29%P/E Ratio-1.7230.4821.9417.81Price / SalesN/A441.91380.9597.68Price / CashN/A168.6838.2634.64Price / Book20.833.466.453.98Net Income-$21.27M-$72.06M$3.22B$247.81M1 Month Performance6.04%-16.76%-9.76%-7.91%1 Year Performance51.06%-26.05%11.49%1.53% Coeptis Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COEPCoeptis Therapeutics0.4365 of 5 stars$10.00+7.9%N/A+40.9%$33.65MN/A-1.722Short Interest ↑News CoveragePositive NewsPRQRProQR Therapeutics2.3804 of 5 stars$1.17-0.8%$9.50+712.0%-38.7%$123.10M$18.91M-3.66180Short Interest ↓News CoverageFDMT4D Molecular Therapeutics2.6533 of 5 stars$2.65-4.3%$26.71+908.1%-87.7%$122.70M$37,000.00-0.93120Analyst RevisionNews CoveragePositive NewsGap DownNMRANeumora Therapeutics3.1557 of 5 stars$0.75+2.3%$9.29+1,132.8%-93.9%$122.00MN/A-0.40108LRMRLarimar Therapeutics3.2153 of 5 stars$1.87-4.6%$19.63+949.5%-70.1%$119.73MN/A-1.6330Positive NewsNGNENeurogene2.135 of 5 stars$7.86-10.6%$53.00+574.3%-63.6%$117.35M$925,000.00-1.8490Gap DownHigh Trading VolumeSCPHscPharmaceuticals3.7796 of 5 stars$2.33+0.4%$14.00+500.9%-43.0%$117.16M$36.33M-1.2330Short Interest ↓Positive NewsOGIOrganigram0.6415 of 5 stars$0.92-2.7%N/A-42.8%$116.74M$166.12M-2.43860Positive NewsADCTADC Therapeutics2.1753 of 5 stars$1.17-1.3%$7.75+565.2%-74.5%$115.43M$70.84M-0.49310KODKodiak Sciences3.7693 of 5 stars$2.18-7.2%$9.00+312.8%-18.0%$114.99MN/A-0.6090Short Interest ↑Analyst RevisionNews CoverageTNXPTonix Pharmaceuticals2.1976 of 5 stars$17.80+13.8%$585.00+3,186.5%-96.9%$114.54M$10.09M0.0050 Related Companies and Tools Related Companies ProQR Therapeutics Alternatives 4D Molecular Therapeutics Alternatives Neumora Therapeutics Alternatives Larimar Therapeutics Alternatives Neurogene Alternatives scPharmaceuticals Alternatives Organigram Alternatives ADC Therapeutics Alternatives Kodiak Sciences Alternatives Tonix Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:COEP) was last updated on 4/19/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coeptis Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coeptis Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
